Holen Sie sich die Stockscreener-App
3.91
1.30%
0.05
Schlusskurs vom Vortag:
$3.86
Offen:
$3.93
24-Stunden-Volumen:
27,464
Relative Volume:
1.02
Marktkapitalisierung:
$88.52M
Einnahmen:
$35.16M
Nettoeinkommen (Verlust:
$-11.44M
KGV:
-6.5593
EPS:
-0.5961
Netto-Cashflow:
$-15.44M
1W Leistung:
-0.26%
1M Leistung:
-10.73%
6M Leistung:
-42.07%
1J Leistung:
-37.87%
1-Tages-Spanne:
$3.8001
$4.00
1-Wochen-Bereich:
$3.66
$4.00
52-Wochen-Spanne:
$3.57
$12.80
Bioharvest Sciences Inc Stock (BHST) Company Profile
Firmenname
Bioharvest Sciences Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare BHST vs KHC, GIS, JBS, MKC, HRL
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHST
Bioharvest Sciences Inc
|
3.905 | 87.50M | 35.16M | -11.44M | -15.44M | -0.5961 |
KHC
Kraft Heinz Co
|
23.89 | 28.21B | 24.99B | -5.76B | 3.95B | -4.863 |
GIS
General Mills Inc
|
33.26 | 17.98B | 18.37B | 2.22B | 1.65B | 4.0676 |
JBS
Jbs Nv
|
12.98 | 14.15B | 88.25B | 1.91B | -681.64M | 1.6761 |
MKC
Mccormick Co Inc
|
46.99 | 12.85B | 7.11B | 1.65B | 680.40M | 6.1005 |
HRL
Hormel Foods Corp
|
20.95 | 11.69B | 12.14B | 489.00M | 577.53M | 0.8886 |
Bioharvest Sciences Inc Stock (BHST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Roth Capital | Buy |
| 2025-05-05 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-18 | Eingeleitet | Maxim Group | Buy |
Bioharvest Sciences Inc Aktie (BHST) Neueste Nachrichten
Tate & Lyle expands BioHarvest partnership for next-gen sweetener innovation - FoodTechBiz
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation - TMX Newsfile
Bioharvest Sciences Signals Progress Amid Near-Term Losses - TipRanks
BioHarvest Sciences and Tate & Lyle expand sweetener development program - Proactive financial news
Tate & Lyle expands collaboration with BioHarvest to accelerate next-generation sweetener innovation - Asia Food Journal
BioHarvest (BHST) Q1 2026 Earnings Transcript - AOL.com
BioHarvest expands Tate & Lyle sweetener development deal By Investing.com - Investing.com Australia
Tate & Lyle expands plant-based sweetener innovation partnership with BioHarvest Sciences - New Food
BioHarvest expands Tate & Lyle sweetener development deal - Investing.com UK
New plant-based sweeteners aim to cut sugar in more foods - Stock Titan
BioHarvest Sciences Q1 earnings call highlights - MSN
BioHarvest outlines 2026 revenue of $38M-$42M in D2C and $12M-$14M in CDMO activity while targeting 2H 2027 fragrance production - MSN
H.C. Wainwright Maintains BioHarvest Sciences(BHST.US) With Buy Rating, Maintains Target Price $14 - Moomoo
BioHarvest Sciences Inc. Common Stock Q1 2026 Earnings Call Summary - Yahoo Finance
BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: - GuruFocus
BioHarvest Sciences (NASDAQ:BHST) Announces Quarterly Earnings Results - MarketBeat
BioHarvest Sciences Inc. (BHST) reports Q4 loss, lags revenue estimates - MSN
BioHarvest Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioHarvest Sciences Posts Q1 2026 Growth and Advances Botanical Synthesis Deals - TipRanks
BioHarvest Sciences: Q1 revenue up 8% YoY, CDMO revenue up 135%, net loss at $2.6M, gross margin at 59% - TradingView
BioHarvest Sciences (NASDAQ: BHST) posts Q1 2026 growth with $8.5M revenue - Stock Titan
Small cap wrap: VivoPower, BioHarvest Sciences, Phunware, Tiziana Life Sciences… - Proactive financial news
BioHarvest Sciences Files Q1 2026 Financials on Form 6-K - TipRanks
BioHarvest Sciences Q1 2026 Earnings Call Transcript - MarketBeat
BioHarvest Sciences (NASDAQ: BHST) grows Q1 2026 revenue while warning on going concern - Stock Titan
BioHarvest Sciences Names New Business Development Chief to Drive CDMO Growth - TipRanks
BioHarvest Sciences: Q1 revenue up 8% to $8.5M, CDMO and D2C segments advance, 2026 outlook reaffirmed - TradingView
New CDMO business development leader joins BioHarvest Sciences (NASDAQ: BHST) - Stock Titan
BioHarvest Sciences Q1 Earnings Call Highlights - MarketBeat
BioHarvest Sciences: Q1 2026 revenue up 8% to $8.5M; key CDMO and D2C milestones achieved; cash at $20.2M - TradingView
BioHarvest Sciences Inc. (BHST) reports Q1 loss, beats revenue estimates - MSN
BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline - Proactive financial news
BioHarvest Sciences : First Quarter 2026 Financial Statements - marketscreener.com
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
BioHarvest Sciences: Q1 revenue up 8% year-over-year, driven by CDMO and VINIA growth; net loss at $2.6 million - TradingView
BioHarvest develops cell culture for endangered perfume ingredient in $1.2M pact - Stock Titan
BioHarvest appoints Salzman-Frenkel as VP business development - Investing.com UK
BioHarvest appoints Salzman-Frenkel as VP business development By Investing.com - Investing.com Nigeria
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division - marketscreener.com
Small cap wrap: TNR Gold, Power Metallic Mines, BioHarvest Sciences, Midnight Sun Mining… - Proactive financial news
BioHarvest Advances Saffron CDMO Program to Stage 2 After Completing Cell Bank Milestone - TipRanks
BioHarvest Sciences (NASDAQ: BHST) completes Stage 1 in $1.125M saffron deal - Stock Titan
Finanzdaten der Bioharvest Sciences Inc-Aktie (BHST)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):